Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
325 studies found for:    anti CD-20 antibodies
Show Display Options
Rank Status Study
1 Unknown  BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Radiation: 131Iodine-Anti-B1 Radioimmunotherapy
2 Completed
Has Results
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Biological: Tositumomab and Iodine I 131 Tositumomab;   Biological: Rituximab
3 Completed
Has Results
Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: tositumomab and iodine I-131 tositumomab
4 Completed
Has Results
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-Cell
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab followed by CHOP
5 Unknown  Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Disease
Intervention: Drug: I-131 Tositumomab therapeutic regimen
6 Completed
Has Results
Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab
7 Completed
Has Results
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
8 Completed Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody
9 Recruiting BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Conditions: B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
Interventions: Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
10 Completed
Has Results
Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.
11 Completed
Has Results
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
12 Completed A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Bortezomib and Tositumomab I-131
13 Active, not recruiting S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: rituximab;   Biological: tositumomab;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: prednisone;   Drug: vincristine;   Radiation: tositumomab
14 Active, not recruiting
Has Results
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Iodine I 131 Tositumomab
15 Completed
Has Results
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Conditions: Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
16 Completed
Has Results
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
Conditions: Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Biological: Tositumomab and Iodine I 131 Tositumomab
17 Completed Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Iodine I 131 Tositumomab
18 Completed Anti-CD20 Antibody Therapy for Sjogren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: Rituximab
19 Completed
Has Results
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)
20 Completed
Has Results
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Biological: Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.